NIH, PKD launch trials for autosomal dominant polycystic kidney disease.The National Institutes of Health (NIH "Not invented here." See digispeak. NIH - The United States National Institutes of Health. ) and the PKD (Polycystic Kidney Disease Polycystic Kidney Disease Definition Polycystic kidney disease (PKD) is one of the most common of all life-threatening human genetic disorders. ) Foundation announced they have jointly launched two treatment trials for autosomal dominant polycystic kidney disease autosomal dominant polycystic kidney disease ADPKD A common–1:400-1:1000 AD condition, which causes 6-9% of ESRD in developed countries Clinical Acute or subacute onset of azotemia and HTN, due to ↑ activity of the RAA system, possibly related to the (ADPKD ADPKD Autosomal dominant polycystic kidney disease, see there ), a common inherited disorder characterized by cysts in the kidneys and other organs, high blood pressure, and aneurysms in the brain. PKD affects an estimated half million people in the US, about 90% of whom have ADPKD. In 2003, 23,000 people with cystic kidney disease (mostly PKD) received dialysis or a kidney transplant, making it the fourth leading cause of kidney failure in the country. ADPKD symptoms usually appear between ages 30 and 40 and include back and side pain and headaches. About half of ADPKD patients eventually develop kidney failure and require dialysis or a kidney transplant. Over the next two years the trials, dubbed the Halt Progression of Polycystic Kidney Disease (HALT-PKD), will recruit more than 1,000 people with ADPKD and treat them for up to four years at centers in Atlanta, GA, Boston, MA, Cleveland, OH, Kansas City, KS, and Rochester, MN, the groups said in a press release. The two trials will compare standard therapy using an angiotensin-converting enzyme inhibitor angiotensin-converting enzyme inhibitor: see ACE inhibitor. (ACE-inhibitor) to intensive therapy using both an ACE-inhibitor and an angiotensin receptor blocker (ARB). Patients will receive a device for measuring blood pressure at home, clinic visits, lab tests, and study mediations at no charge. They will also have their kidney function estimated using a standard blood test measurement called cGFR and other measures to track progression of kidney disease. HALT-PKD Study A, for people 15 to 49 years of age with early disease (cGFR>60), will also compare standard (120-130/70-80 mm Hg) and low (95-110/60-75 mm Hg) blood pressure targets and measure changes in cyst and kidney size using a Magnetic Resonance Imaging magnetic resonance imaging (MRI), noninvasive diagnostic technique that uses nuclear magnetic resonance to produce cross-sectional images of organs and other internal body structures. method developed by the National Institute of Diabetes and Digestive and Kidney Disease's (NIDDK NIDDK National Institute of Diabetes and Digestive and Kidney Diseases ) Consortium for Radiologic Imaging Studies of PKD. Study B, for people 18 to 64 and more advanced disease (eGFR 30-60), will track the time it takes eGFR to drop by 50%, the need for kidney failure treatment, and patient deaths. More information about PKD can be found online at www.niddk.nih.gov and the PKD Foundation at www.pkdcure.org or calling (800) PKD-CURE (753-3873) |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion